SCRM Seminar

Dr Brian Rudkin, Senior Scientist from the Centre National de la Recherche Scientifique in Paris, will give this talk in Auditorium B, Chancellor's Building, Little France.

Friday 4th February 2011

Peptide aptamers: precision tools for dissecting signaling pathways

• Time: 12.00pm - 1.30pm

Please contact the Host, Paul De Sousa, if you would like to meet Dr. Rudkin. You can either call him on 0131 242 6646 or email:

All interested are welcome to attend

MRC Centre for Regenerative Medicine, The University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, EDINBURGH, EH16 4SB

Abstract:

While systems biology approaches analyzing the genome, proteome, interactome etc. are increasing our understanding of complex regulatory networks, identification of key proteins in signaling pathways that regulate cellular responses remains crucial for furthering our understanding of normal cellular processes and pathological perturbations thereof. Peptide aptamers, conceived to conceptually resemble antibodies, are small combinatorial proteins with a constant scaffold presenting a variable region. Their use for the identification and validation of novel targets and discovery of novel therapeutics in vitro, in cellular models, and in vivo in animal models for human disease, will be discussed.

Bio:

Dr. Rudkin is Senior Scientist at the CNRS, Head of a research group at the Ecole Normale Supérieure de Lyon, Laboratory of Molecular and Cellular Biology since 1990 and Zijiang Professor at the East China Normal University in Shanghai since 2007. He is Co-Director of the joint laboratory on Neuropathogenesis at the ECNU along with Prof. ChongGang YUAN. Dr. Rudkin is a member of the Executive committee for the coordination of the Handicap, Aging and Neuroscience Cluster of the Rhone-Alps Region that brings together research laboratories, small innovative companies, large multinationals, university hospitals and patient organizations to better serve the needs of society regarding these concerns. He has accompanied a number of innovative companies in their creation and development, over the years, as external advisor or partner.